Lucentis SAILOR Trial Hits Choppy Water
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.